申请人:ASTRAZENECA AB
公开号:WO2009004382A2
公开(公告)日:2009-01-08
In one aspect, the present invention relates to compounds of Formula (I) and to pharmaceutically acceptable sa lts thereof, wherein: n is 1 to 4; and R3 in each occurrence is independently selected from -X-R5, -W-R6, -C(O)-N(R3a)-S(O)2-R3b, -C(R3a)=N-R3y, -C(R3a)=N-N(R3a)-C(O)-R3b, -C(R3a)=N-N(R3a)-C(O)2-R3b, -C(R3a)=N-N(R3y)2, -C(R3a)=N-N(R3a)-C(O)-N(R3y)2, -C(N(R3a)2)=N-R3y, -C(N(R3a)2)=N-OR3y, -C(N(R3a)2)=N-C(O)-R3b, -C(N(R3a)2=N-S(O)2-R3b, -C(N(R3a)2)=N-CN, -N=C(R3y)2, -N(R3a)-S(O)2-N(R3y)2, -N(R3a)-N(R3y)2, -N(R3a)-C(O)-N(R3y)2, -N(R3a)-C(O)-N(R3a)-S(O)2-R3b, -N(R3a)-C(R3a)=N(R3y), -N(R3a)-C(R3a)=N-OR3y, -N(R3a)-C(R3a) =N-C(O)-R3b, -N(R3a)-C(R3a)=N-S(O)2R-3b, -N(R3a)-C(R3a)=N-CN, -N(R3a)-C(N(R3a)2)=N-R3y, -N(R3a)-C(N(R3a)2)=N-OR3y, -N(R3a)-C(N(R3a)2)=N-C(O)-R3b, -N(R3a)-C(N(R3a)2)-N-S(O)2-R3b, -N(R3a)-C(N(R3a)2)-N-CN, -O-C(O)-R3b, and -Si(R3b)3; to methods of using them to treat bacterial infections, and to methods for their preparation.